The Efficacy and Safety of Daptomycin in the Treatment of Gram-positive Bacterial Infection.

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Total Enrollment

2000 participants

Study Classification

OBSERVATIONAL

Study Start Date

2020-08-25

Study Completion Date

2022-08-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This study aims to collect and analyze clinical data of daptomycin to explore the efficacy and safety of daptomycin in the treatment of Gram-positive bacterial infections. And optimize the dosing regimen based on these data.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Study to Investigate the Safety, Tolerability, and Pharmacokinetics of DSTA4637S in Participants With Staphylococcus Aureus Bacteremia Receiving Standard-of-Care (SOC) Antibiotics

NCT03162250

Bacteremia

COMPLETED PHASE1

The Efficacy and Adverse Reactions of Neotetracycline in the Treatment of GNB Infections

NCT06990126

Clinical Efficacy and Safety

ENROLLING_BY_INVITATION

Safety and Efficacy of Daptomycin for the Treatment of Complicated Skin and Skin-structure Infections

NCT00463801

Staphylococcal Skin Infections

TERMINATED PHASE4

Efficacy of Daptomycin Plus Fosfomycin Versus Daptomycin for Treatment of MRSA Bacteremia

NCT01898338

Staph Aureus Methicillin Resistant Bacteremia

COMPLETED PHASE3

Antibiotics Use and Carriage of Methicillin-resistant Staphylococci in Community Patients

NCT01489878

Methicillin Resistant Staphylococcus Aureus

COMPLETED

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

With the gradual increase in the detection rate of drug-resistant bacteria, bloodstream infections, skin and soft tissue infections, infective endocarditis and other infectious diseases caused by MRSA, MRCNS, and VRE have greatly increased patient mortality and medical burden.

Daptomycin has strong anti-bacterial activity and rapid sterilization. It is almost 100% sensitive to common Gram-positive bacteria. Both domestic and foreign guidelines recommend its use for the treatment of infectious diseases such as bacteremia, central venous catheter-related bloodstream infections, infective endocarditis, skin and soft tissue infections, bone and joint infections，and so on. However, there is a lack of actual clinical use of daptomycin in China, as well as efficacy and safety assessments based on real world data.

The purpose of this study is to collect and analyze data on the use of daptomycin in the real world. The clinical cure rate and inefficiency, temperature drop time, 28-day mortality rate are the primary outcome measures, and the overall incidence of adverse events, the results of CPK monitoring and its correlation with dose, renal function, length of hospital stay, and treatment costs are secondary outcome measures to investigate the efficacy and safety of daptomycin in the treatment of gram-positive bacterial infection.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Antibiotic

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

OTHER

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Gram-positive cocci infection

No intervention. The clinical data of patients (including demographic information, details of anti-infective therapy, imaging and laboratory testings) will be collected and analyzed.

Daptomycin

Intervention Type DRUG

According to the severity of the disease, the site of infection and clinical response, the doctor makes a drug regimen of datoramycin.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Daptomycin

According to the severity of the disease, the site of infection and clinical response, the doctor makes a drug regimen of datoramycin.

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* 1 years of age or older
* Meet one of the following conditions:

1. Confirmed Gram-positive cocci (GPC) infection;
2. Cases evaluated by doctors as suspected gram-positive coccal infection with potentially high benefit from drug use；
3. Severe infection patients to be combined with empirical treatment of daptomycin.
* The off-label drug use conforms to the relevant administrative regulations of each participating unit.

Exclusion Criteria

* Allergic to datoramycin;
* Pregnant and lactating women；
* Patients with age \< 1 year；
* Participate in other clinical trials；
* Patients with nervous system GPC infection;
* Patients with pulmonary GPC infection.

Minimum Eligible Age

1 Year

Eligible Sex

ALL

Accepts Healthy Volunteers

No